These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 27577082)

  • 1. Effectiveness of capecitabine with or without docetaxel therapy for the treatment of patients with advanced urothelial carcinoma: a single-institution experience.
    Xue C; An X; Cao Y; Chen T; Yang W; Deng Y; Han H; Teng X; Zhou F; Shi Y
    Oncotarget; 2016 Sep; 7(39):63722-63729. PubMed ID: 27577082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma.
    Kim YS; Lee SI; Park SH; Park S; Hwang IG; Lee SC; Sun JM; Lee J; Lim HY
    Clin Genitourin Cancer; 2016 Feb; 14(1):76-81. PubMed ID: 26454620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial.
    Petrylak DP; de Wit R; Chi KN; Drakaki A; Sternberg CN; Nishiyama H; Castellano D; Hussain S; Fléchon A; Bamias A; Yu EY; van der Heijden MS; Matsubara N; Alekseev B; Necchi A; Géczi L; Ou YC; Coskun HS; Su WP; Hegemann M; Percent IJ; Lee JL; Tucci M; Semenov A; Laestadius F; Peer A; Tortora G; Safina S; Del Muro XG; Rodriguez-Vida A; Cicin I; Harputluoglu H; Widau RC; Liepa AM; Walgren RA; Hamid O; Zimmermann AH; Bell-McGuinn KM; Powles T;
    Lancet; 2017 Nov; 390(10109):2266-2277. PubMed ID: 28916371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer.
    Choueiri TK; Ross RW; Jacobus S; Vaishampayan U; Yu EY; Quinn DI; Hahn NM; Hutson TE; Sonpavde G; Morrissey SC; Buckle GC; Kim WY; Petrylak DP; Ryan CW; Eisenberger MA; Mortazavi A; Bubley GJ; Taplin ME; Rosenberg JE; Kantoff PW
    J Clin Oncol; 2012 Feb; 30(5):507-12. PubMed ID: 22184381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment and prognosis of 117 patients with advanced urothelial carcinoma of the bladder].
    Song Y; Yang L; Zhou A; Chi Y; Wang J
    Zhonghua Zhong Liu Za Zhi; 2014 Mar; 36(3):212-6. PubMed ID: 24785283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study.
    Ardavanis A; Tryfonopoulos D; Alexopoulos A; Kandylis C; Lainakis G; Rigatos G
    Br J Cancer; 2005 Feb; 92(4):645-50. PubMed ID: 15685232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial.
    Petrylak DP; Tagawa ST; Kohli M; Eisen A; Canil C; Sridhar SS; Spira A; Yu EY; Burke JM; Shaffer D; Pan CX; Kim JJ; Aragon-Ching JB; Quinn DI; Vogelzang NJ; Tang S; Zhang H; Cavanaugh CT; Gao L; Kauh JS; Walgren RA; Chi KN
    J Clin Oncol; 2016 May; 34(13):1500-9. PubMed ID: 26926681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy with cisplatin, epirubicin and docetaxel in transitional cell urothelial cancer. Phase II trial.
    Pectasides D; Visvikis A; Aspropotamitis A; Halikia A; Karvounis N; Dimitriadis M; Athanassiou A
    Eur J Cancer; 2000 Jan; 36(1):74-9. PubMed ID: 10741298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum-containing chemotherapy. A Cochrane Rapid Review.
    Narayan V; Kahlmeyer A; Dahm P; Skoetz N; Risk MC; Bongiorno C; Patel N; Hwang EC; Jung JH; Gartlehner G; Kunath F
    Cochrane Database Syst Rev; 2018 Jul; 7(7):CD012838. PubMed ID: 30036453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docetaxel and gemcitabine combination therapy in advanced transitional cell carcinoma of the urothelium: results of a phase II and pharmacologic study.
    Dumez H; Martens M; Selleslach J; Guetens G; De Boeck G; Aerts R; De Bruijn EA; Maes RA; van Oosterom AT
    Anticancer Drugs; 2007 Feb; 18(2):211-8. PubMed ID: 17159607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemcitabine plus docetaxel as first-line biweekly therapy in locally advanced and/or metastatic urothelial carcinoma: a phase II study.
    Neri B; Vannini L; Giordano C; Grifoni R; Pantaleo P; Baldazzi V; Crisci A; Lapini A; Raugei A; Carini M
    Anticancer Drugs; 2007 Nov; 18(10):1207-11. PubMed ID: 17893522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine plus carboplatin; and gemcitabine, docetaxel, and carboplatin combined chemotherapy regimens in patients with metastatic urothelial carcinoma previously treated with a platinum-based regimen: preliminary report.
    Hoshi S; Ohyama C; Ono K; Takeda A; Yamashita S; Yamato T; Itoh A; Satoh M; Saito S; Okada Y; Sohma F; Arai Y
    Int J Clin Oncol; 2004 Apr; 9(2):125-9. PubMed ID: 15108045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma. A preliminary report of tolerance and local control.
    Varveris H; Delakas D; Anezinis P; Haldeopoulos D; Mazonakis M; Damilakis J; Metaxaris G; Chondros N; Mavromanolakis E; Daskalopoulos G; Dimitrakopoulos A; Kranidis A
    Anticancer Res; 1997; 17(6D):4771-80. PubMed ID: 9494605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic non-small cell lung cancer.
    Pallis AG; Agelaki S; Agelidou A; Varthalitis I; Syrigos K; Kentepozidis N; Pavlakou G; Kotsakis A; Kontopodis E; Georgoulias V
    BMC Cancer; 2010 Nov; 10():633. PubMed ID: 21092076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Larotaxel with Cisplatin in the first-line treatment of locally advanced/metastatic urothelial tract or bladder cancer: a randomized, active-controlled, phase III trial (CILAB).
    Sternberg CN; Skoneczna IA; Castellano D; Theodore C; Blais N; Voog E; Bellmunt J; Peters F; Le-Guennec S; Cerbone L; Risse ML; Machiels JP
    Oncology; 2013; 85(4):208-15. PubMed ID: 24080920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment outcome of docetaxel, capecitabine and cisplatin regimen for patients with refractory and relapsed nasopharyngeal carcinoma who failed previous platinum-based chemotherapy.
    Gao Y; Huang HQ; Bai B; Cai QC; Wang XX; Cai QQ
    Expert Opin Pharmacother; 2014 Feb; 15(2):163-71. PubMed ID: 24295173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: a multicenter phase II study of the Hellenic Cooperative Oncology Group.
    Dimopoulos MA; Bakoyannis C; Georgoulias V; Papadimitriou C; Moulopoulos LA; Deliveliotis C; Karayannis A; Varkarakis I; Aravantinos G; Zervas A; Pantazopoulos D; Fountzilas G; Bamias A; Kyriakakis Z; Anagnostopoulos A; Giannopoulos A; Kosmidis P
    Ann Oncol; 1999 Nov; 10(11):1385-8. PubMed ID: 10631471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docetaxel for the treatment of bladder cancer.
    Albany C; Sonpavde G
    Expert Opin Investig Drugs; 2015; 24(12):1657-64. PubMed ID: 26535615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do patients with metastatic urothelial carcinoma benefit from docetaxel as second-line chemotherapy?
    Morales-Barrera R; Suárez C; Valverde C; Nuñez I; Maldonado X; Morote J; Carles J
    Clin Transl Oncol; 2014 Jan; 16(1):102-6. PubMed ID: 23606355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer.
    Chan S; Romieu G; Huober J; Delozier T; Tubiana-Hulin M; Schneeweiss A; Lluch A; Llombart A; du Bois A; Kreienberg R; Mayordomo JI; Antón A; Harrison M; Jones A; Carrasco E; Vaury AT; Frimodt-Moller B; Fumoleau P
    J Clin Oncol; 2009 Apr; 27(11):1753-60. PubMed ID: 19273714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.